The Cat is Out of the Bag!! Learn about the latest feline HCM research from scientists, researchers and cat owners. Viewpoint with Dennis Quaid and TriviumVet have teamed up to...
Blog
Posts about Halt Study:
Subscribe to our blog
TriviumVet launch the HALT HCM Study recruiting 300 cats with diagnosed subclinical Hypertrophic Cardiomyopathy (HCM)
We at TriviumVet are thrilled to announce that the long-awaited HALT HCM Study is now live and recruiting cats in cardiac care centers across the United States! The study was...
Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our novel,...
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations You can read the full article below....
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
Dr. Joshua Sterns presentation from VMX 2023
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway
TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM)...
TriviumVet advance their first feline product, a potential treatment for HCM in cats
TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned...
Feline HCM product prevented progression of hypertrophy - Results of the RapaCat Study published in JAVMA
TriviumVet are proud to announce the publication of the results of the RapaCat Study in the Journal of the American Veterinary Medical Association. This study used our novel,...
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations
S&P Global Animal Health Interview TriviumVet CEO Louise Grubb on upcoming product authorizations You can read the full article below....
Cutting edge Feline Hypertrophic Cardiomyopathy Research to be presented to the American College of Veterinary Internal Medicine (ACVIM)
Two exciting pieces of feline hypertrophic cardiomyopathy (HCM) research are to be presented to the American College of Veterinary Internal Medicine (ACVIM) this year on their...
Understanding Feline HCM: Prognosis, Genetic Mutations and Emerging Treatment Options Dr. Joshua Stern, UC Davis
Dr. Joshua Sterns presentation from VMX 2023
RAPACAT HCM trial results unveiled at International Cardio-Renal Veterinary Symposium (ICVS) 2022
Feline hypertrophic cardiomyopathy remains the greatest unmet need in veterinary cardiology, affecting around 15% of all pet cats. After two years of collaboration between...
FDA’s Center for Veterinary Medicine deems TriviumVet’s feline HCM program eligible for expanded conditional approval pathway
TriviumVet™ are delighted to announce that the Food and Drug Administration’s Center for Veterinary Medicine has determined that our feline hypertrophic cardiomyopathy (HCM)...
TriviumVet advance their first feline product, a potential treatment for HCM in cats
TriviumVet commence clinical study of first-in-disease treatment for HCM in cats We are delighted to announce the initiation of a ground-breaking clinical study in client-owned...